RxDoctor Payments Data

Ala Dahhan, MD

Nephrology · Rochester, NYNPI 1013099787

Payments from drug & device makers

$684in general payments, 2019–2025

Across 44 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$227
  • Otsuka America Pharmaceutical, Inc.$125
  • Calliditas Therapeutics US Inc.$114
  • Travere Therapeutics, Inc.$107
  • GSK$36
  • Novartis$33
  • plus $43 from 2 others

What the payments were for

  • Food & beverage$49472%
  • Education$19028%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$684 in reported general payments places this provider in the 45th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York

Medicare billing

Part B allowed, 2024
$257,782
Medicare patients
290
Services billed
1,838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XphozahTenapanor Hcl18$49,762
VeltassaPatiromer Calcium Sorbitex24$20,700
RenvelaSevelamer Carbonate11$15,370
LokelmaSodium Zirconium Cyclosilicate30$14,349
Sevelamer Carbonate93$12,171
Calcitriol275$4,600
Calcium Acetate41$3,761
Potassium Citrate ErPotassium Citrate20$3,689
Midodrine Hcl27$1,499
Sodium Polystyrene Sulfonate14$797
Allopurinol74$745
Torsemide47$725
Chlorthalidone29$721
Amlodipine Besylate94$630
Labetalol Hcl27$564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$227$14,34930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 935 nephrology providers in New York.

Other nephrology in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →